{{noteTA
|T=zh-hant:托普樂肯; zh-hans:拓扑替康;
|1=zh-hant:托普樂肯; zh-hans:拓扑替康;
}}
{{medical}}
{{drugbox 
| IUPAC_name = (''S'')-10-[(dimethylamino)methyl]-4-ethyl-4,9-<br>dihydroxy-1''H''-pyrano[3',4':6,7]indolizino[1,2-b]<br>quinoline-3,14(4''H'',12''H'')-dione
| image = Topotecan Structural Formula V.1.svg
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 123948-87-8 
| ATC_prefix = L01 
| ATC_suffix = XX17 
| PubChem = 60700 
| DrugBank = APRD00687 
| IUPHAR_ligand = 7101
| CAS_number2_Ref = {{cascite|changed|??}}
| CAS_number2 = 119413-54-6
| CAS_supplemental2 = (hydrochloride)
| DrugBank2_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank2 = DB01030
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 54705
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7M7YKX2N15
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08618
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 84
| C = 23 |H = 23 |N = 3 |O = 5
| molecular_weight = 421.446 [[克|g]]/[[摩尔|mol]] 
| bioavailability = NA
| protein_bound = 35% 
| metabolism = [[肝脏|肝脏]]
| elimination_half-life = 2-3小时
| excretion = [[肾脏|肾脏]]
| pregnancy_AU = D
| pregnancy_US = D
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = 静脉注射
}}
'''托普樂肯'''（'''Topotecan'''；商品名：'''Hycamtin'''®，'''癌康定'''）是一種化學治療藥物，為拓樸異構酶I抑制物，一般用來治療[[卵巢癌|卵巢癌]]與[[肺癌|肺癌]]等癌症。

==给药方式==
为[[静脉注射|静脉注射]]，不过有口服的研究。

==副作用==
*[[腹泻|腹泻]]
*低[[全血细胞计数|血细胞计数]]
*骨髓抑制
*容易受到[[感染|感染]]

==參見==
*[http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=41185 NCI Drug Dictionary Definition of Topotecan] {{Wayback|url=http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=41185 |date=20101221203853 }}
*[http://www.cancer.gov/cancertopics/druginfo/topotecanhydrochloride NCI Drug Information for Patients] {{Wayback|url=http://www.cancer.gov/cancertopics/druginfo/topotecanhydrochloride |date=20150426133712 }}

{{化疗药物}}

{{pharm-stub}}
[[Category:拓扑异构酶抑制剂|Category:拓扑异构酶抑制剂]]
[[Category:吡喃吲嗪喹啉|Category:吡喃吲嗪喹啉]]
[[Category:Δ-内酯|Category:Δ-内酯]]
[[Category:内酰胺|Category:内酰胺]]